subscribeSubscribe
QSYMIA (Phentermine-Topiramate) Drug Insights and Market Forecasts to 2032

QSYMIA (Phentermine-Topiramate) Drug Insights and Market Forecasts to 2032
PR NEWSWIRE
03 Jan 2023
Share Share
ICER reaffirms Qsymia as most cost-effective obesity treatment in final report

ICER reaffirms Qsymia as most cost-effective obesity treatment in final report
Paul Schloesser ENDPTS
31 Aug 2022
Share Share
FDA Approves Qsymia for Treating Teens With Obesity

FDA Approves Qsymia for Treating Teens With Obesity
Miriam E. Tucker MEDSCAPE
29 Jun 2022
Share Share
Fighting obesity by attacking both food intake and energy burn

Fighting obesity by attacking both food intake and energy burn
Arlene Weintraub FIERCE BIOTECH
29 Jun 2019
Share Share
In another misstep for Vivus, FDA`s promo police ding misleading Qsymia webpage

In another misstep for Vivus, FDA`s promo police ding misleading Qsymia webpage
Beth S. Bulik FIERCE PHARMA
07 Jun 2019
Share Share
OPDP Issues Second Untitled Letter of 2019

OPDP Issues Second Untitled Letter of 2019
Michael Mezher RAPS
30 May 2019
Share Share
Belviq Study Results May Improve The Fortunes Of Weight-Loss Drugs

Belviq Study Results May Improve The Fortunes Of Weight-Loss Drugs
Joshua Cohen FORBES
11 Sep 2018
Share Share
UC San Diego researchers uncover root of leptin resistance

UC San Diego researchers uncover root of leptin resistance
Brittany Meiling ENDPTS
24 Aug 2018
Share Share
With debt looming, browbeaten diet pill maker Orexigen goes bankrupt

With debt looming, browbeaten diet pill maker Orexigen goes bankrupt
B. Meiling ENDPTS
13 Mar 2018
Share Share
Enforcement Report - Week of September 20, 2017

Enforcement Report - Week of September 20, 2017
FDA
20 Sep 2017
Share Share